Module 3: IBD Digavalli Flashcards
Dr, Digavalli EXAMV
Affected areas of Inflammatory Bowel Disease (IBD) vs Crohn’s disease
IBD: starts in the rectum -> may affect the entire colon continuously
Crohn’s disease: non-continuous, patchy areas, often the ileocecal junction; may affect large or small intestine
Which layers of the tissues are affected?
IBD: superficial -> limited to the mucosal layer
Crohn’s: affects multiple layers -> may lead to strictures, perforation, fistula formation
Characteristics of Crohn’s disease
-skip lesions or cobblestone patterns
-transmural lesions: affecting multiple layers -> leading to strictures, perforation, fistula
What are diseases that arise as a consequence of IBD?
-risk of colorectal cancer (regular colonoscopy recommended)
-Extra GI:
skin
dry eyes
Arthropathy
Arthritis
thromboembolic events
stricture of the bile duct (in Chron’s disease)
Disease progression in IBD
-symptoms wax and wane but with gradual damage to the GI with each episode (flares)
-damage: strictures, fistula, abscesses
Possible progression to IBD
- Genetic predisposition and environmental factors (hygiene, diet, smoking)
- disease: infection, drug use (NSAIDs damaging the gut wall or antibiotics killing good bacteria) ->
- bacteria crossing the wall and causing an inflammatory reaction -> uncontrolled immune response (interleukin, TNF)
- bowel damage, tissue remodelling -> IBD
Mild treatment options
-5-amino salicylates (5-ASA; mesalamine)
-topical corticosteroids (proctitis)
-budesonide (ileitis)
-antibiotics
5-amino salicylates (mesalamine)
-for mild IBD
-MOA not clear
-works locally in the gut
-Sulfasalazine is broken down to 5-ASA (mesalamine) ->
-5-ASA forms an azo linkage -> 5-ASA derivates which is not very well absorbed (stays in the GI)
-bacteria’s azole reductase breaks up the azole linkage -> RELIEF
What is the supposed MOA of 5-ASA
-prostanoid release -> NFκB suppression
-NFκB stimulates cytokine production
Which drug has different formulations to target specific areas of the GI?
5-ASA derivates
DDS approaching such as enteric coating (protection against gastric dissolution or early release in the small intestine)
MOA of Glucosteroids
-binds glucocorticosteroid receptor -> deactivating transcription factors
-prevents the synthesis of inflammatory proteins
-suppress inflammatory signals (NFκB)
What is the severity of IBD treated with glucocorticoids?
Mild, moderate IBD
moderate/severe flares
-after treating flares -> patients switch to other drugs bc of the side effect profile
Side effects of Glucocorticosteroids
-susceptibility to infections (due to immune suppression)
-interfere glucose metabolism -> gluconeogenesis from non-carbon source -> increases glucose level
-lipid levels go up (via lipolysis)-> arteriosclerosis
-Cushing syndrome (moon face)
Other side effects of steroids
-Hypothalamus -Pituitary gland -Adrenal medulla axis -> constant cortisol release -> HPA insufficiency bc the steroid mimics the cortisol -> the body thinks there is enough cortisol and stops producing cortisol (inhibiting the HPA-axis), may cause depression
-osteoporosis
-glaucoma
-muscle myopathy
-hirsutism
-skin breakage
-gastric ulcer (with NSAIDs)
Glucocorticoids drugs
Oral, IV when severe
-Prednisone (prodrug)
-Prednisolone (active part)
-Budesonide (synthetic, less systemic due to high first-pass metabolism)